ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Industry
Pharmaceutical Preparations
Location
Biopole, Route De La Corniche 3 B, Epalinges, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
Q4 2023 - Mar 13, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.5 M shares
Common Stock, Shares, Outstanding 82.3 M shares +2.05%
Entity Public Float 153 M USD
Common Stock, Value, Issued 7.31 M USD 0%

Income Statement

Label TTM Value / Value Unit Change %
Nonoperating Income (Expense) -687 K USD +98.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 279 M USD -14.7%
Inventory, Net 16.2 M USD +34%
Assets, Current 336 M USD -22.7%
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 5.62 M USD +67.6%
Operating Lease, Right-of-Use Asset 10.5 M USD +52.2%
Other Assets, Noncurrent 711 K USD -21.2%
Assets 355 M USD -27.7%
Accounts Payable, Current 15.6 M USD +26.1%
Accrued Liabilities, Current 50.6 M USD -26.1%
Liabilities, Current 67.7 M USD -17.4%
Deferred Income Tax Liabilities, Net 1.33 M USD -66.7%
Operating Lease, Liability, Noncurrent 10.2 M USD +55.1%
Other Liabilities, Noncurrent 8.88 M USD +960%
Liabilities 503 M USD +22.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -93 K USD -105%
Retained Earnings (Accumulated Deficit) -1.34 B USD -21.9%
Stockholders' Equity Attributable to Parent -148 M USD -287%
Liabilities and Equity 355 M USD -27.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares, Issued 89 M shares 0%
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 279 M USD -14.7%
Deferred Tax Assets, Valuation Allowance 212 M USD +61.7%
Deferred Tax Assets, Gross 213 M USD +23.9%
Operating Lease, Liability 11.6 M USD
Lessee, Operating Lease, Liability, to be Paid 13.7 M USD
Property, Plant and Equipment, Gross 9.9 M USD +46.3%
Operating Lease, Liability, Current 1.47 M USD +33.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.94 M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure +76.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.01 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.98 M USD
Deferred Tax Assets, Operating Loss Carryforwards 163 M USD +24.2%
Unrecognized Tax Benefits 6.62 M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.99 M USD
Additional Paid in Capital 1.18 B USD +1.21%
Deferred Tax Assets, Net of Valuation Allowance 1.33 M USD -96.8%